glp-1 drugs and parkinson's disease Are diabetes like Ozempic coming for disease? — Parkinson Secrets GLP-1 drug shows little benefit
Description
Absolutely not
h , Quantification of cFOS + cells in nucleus of the solitary tract (NTS)
But what are semaglutide (GLP-1 RA) drugs, and how do they work
A randomised controlled trial of treatment for idiopathic intracranial hypertension
Findings are not yet published but available from the US FDA including placebo-corrected and dose-dependent declines in bone mineral density of 0.9%1.2% at total hip, 0.3%0.7% at lumbar spine, and 0.1% at femoral neck with the use of canagliflozin
At the same time, issues of cost and access necessitate policy reforms to ensure equitable availability of these treatments
